Role of systematic pelvic and para‐aortic lymphadenectomy in delayed debulking surgery after six neoadjuvant chemotherapy cycles for high‐grade serous ovarian carcinoma

2021 ◽  
Author(s):  
Andre Lopes ◽  
Maria L. N. D. Genta ◽  
Vanessa Costa Miranda ◽  
Andrea Aranha ◽  
Rossana V. M. Lopez ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
High Grade ◽  
Debulking Surgery ◽  
Serous Ovarian Carcinoma

Surgical factors do not impact survival in high-grade serous ovarian carcinoma patients treated with neoadjuvant chemotherapy

2015 ◽  
Vol 137 ◽  
pp. 43
Author(s):  
J.M. Stewart ◽  
A.A. Tone ◽  
M.Q. Bernardini ◽  
S.E. Ferguson ◽  
J. Dodge ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
High Grade ◽  
Serous Ovarian Carcinoma

Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma

2016 ◽  
Vol 141 ◽  
pp. 151-152
Author(s):  
R.C. Arend ◽  
Z.C. Dobbin ◽  
D.K. Crossman ◽  
B.K. Erickson ◽  
J.D. Boone ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
Molecular Response ◽  
High Grade ◽  
Serous Ovarian Carcinoma ◽  
Response To Neoadjuvant Chemotherapy

scholarly journals Low RAP80 mRNA Expression Correlates with Shorter Survival in Sporadic High-Grade Serous Ovarian Carcinoma

2017 ◽  
Vol 32 (1) ◽  
pp. 90-95 ◽  
Author(s):  
Margarita Romeo ◽  
Niki Karachaliou ◽  
Imane Chaid ◽  
Cristina Queralt ◽  
Itziar De Aguirre ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Mrna Expression ◽  
Residual Disease ◽  
Progression Free Survival ◽  
Figo Stage ◽  
High Grade ◽  
Platinum Compounds ◽  
Serous Ovarian Carcinoma ◽  
Platinum Based Chemotherapy

Objective Homologous recombination (HR) is frequently impaired in sporadic high-grade serous ovarian carcinoma (sHGSOC) due to deficiencies in BRCA1/2 genes, a situation associated with hypersensitivity to platinum compounds. Alterations in other genes can also cause HR deficiency. Preclinical data show that RAP80 is an HR–pathway-related gene that influences BRCA1 activity. RAP80 has been reported to affect outcome in some solid neoplasms. This study investigates the role of RAP80 in sHGSOC survival. Methods mRNA expression of RAP80 was analyzed in tumor samples from 35 patients who postoperatively received standard platinum-based chemotherapy. The effects of RAP80 expression on progression-free survival (PFS) and overall survival (OS) were examined by means of Cox regressions. The clinical variables known to have prognostic value (FIGO stage, residual disease at surgery, and debulking surgery) were included as covariates in the analysis. BRCA1 was analyzed given the moderate correlations with RAP80. Results Median follow-up, PFS and OS were 61.3, 20.2 and 62.8 months, respectively. Low RAP80 expression levels were associated with shorter PFS ( HR = 1.449, p = 0.007) and OS ( HR = 1.331, p = 0.047). Conclusions This is the first study to show a potential prognostic role of RAP80 expression in patients with HGSOC. The results suggest that HR deficiency due to low RAP80 expression is not associated with hypersensitivity to platinum compounds in sHGSOC.

scholarly journals The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma

Oncotarget ◽  
2015 ◽  
Vol 6 (31) ◽  
pp. 31593-31603 ◽  
Author(s):  
Euan A. Stronach ◽  
Paula Cunnea ◽  
Christina Turner ◽  
Tankut Guney ◽  
Radhika Aiyappa ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Interleukin 8 ◽  
High Grade ◽  
Serous Ovarian Carcinoma

Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma

2017 ◽  
Vol 27 (4) ◽  
pp. 708-713 ◽  
Author(s):  
Edwina Coghlan ◽  
Tarek M. Meniawy ◽  
Aime Munro ◽  
Max Bulsara ◽  
Colin JR Stewart ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
Tumor Regression ◽  
Univariate Analysis ◽  
Prognostic Significance ◽  
Rank Test ◽  
Chemotherapy Response ◽  
High Grade ◽  
Prognostic Role

ObjectiveOur objective was to validate the prognostic role of the chemotherapy response score (CRS), which has been proposed for measuring tumor response to neoadjuvant chemotherapy in patients with high-grade serous tubo-ovarian carcinoma, in predicting progression-free survival (PFS) and overall survival (OS).MethodsA retrospective cohort study was conducted of patients with advanced high-grade serous tubo-ovarian carcinoma diagnosed between January 1, 2010, and December 31, 2014, and treated with neoadjuvant chemotherapy. Treatment-related tumor regression was determined according to the 3-tier CRS, and results were compared with standard clinicopathological variables. Survival analysis was performed using Cox proportional hazards models and the log-rank test.ResultsSeventy-one patients were eligible for analysis. Median OS was 25.5 months. Fifty-eight patients (82%) had disease recurrence and 32 (45%) had died at study census. Of the 71 patients, 19, 29, and 23 patients had a CRS of 1, 2, and 3, respectively. On univariate analysis, the CRS significantly predicted PFS (hazard ratio [HR], 3.77; 95% confidence interval [CI], 1.83–7.78; P = 0.000) and OS (HR, 2.81; 95% CI, 1.16–6.79; P = 0.022). In a multivariate model, the CRS was significantly associated with PFS (HR, 2.81; 95% CI, 1.16–6.79; P = 0.022) but not with OS (HR, 2.39; 95% CI, 0.47–3.08; P = 0.079). Patients with CRS of 1 and 2 combined were twice as likely to progress during the study period compared with patients with a CRS of 3 (HR, 2.0; 95% CI, 1.06–3.78; P = 0.032; median PFS, 16 vs 26 months). No significant association was observed for OS (CRS 1/2 vs 3; HR, 1.57; 95% CI, 0.68–3.65; P = 0.291).ConclusionsIn this study, the CRS showed independent prognostic significance for PFS but not for OS.

Sign in / Sign up

Export Citation Format

Share Document